Please login to the form below

Unique forum will unite NHS and industry to drive innovation

HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare

The Life Sciences Industrial Strategy made it clear that collaboration between the NHS and industry is essential to foster innovation. To help facilitate this process, HSJ which is part of Wilmington Healthcare, will host a unique Life Sciences Forum on Wednesday, June 6.  

Senior representatives from pharma, med tech and the NHS are invited to attend this exclusive event at BMA House in London, which will feature presentations from high profile speakers within the healthcare sector and opportunities for guests to join in the discussions.  

The event aims to help industry develop stronger relationships with leaders from NHS England, Regional Medicines Optimisation Committees (RMOCs), Sustainability and Transformation Partnerships (STPs) and Integrated Care Systems (ICSs), and influence debate around the future direction of travel for medicines.
 

It will also help industry to better understand the challenges facing the NHS by learning about its priorities at a local and national level. Guests can find out about partnership working approaches through collaboration with Academic Health Science Networks (AHSNs) too.  

The Life Sciences Forum is designed to enable both parties to have honest and candid discussions on how to develop relationships and drive innovation to ensure patient outcomes are improved and efficiencies are realised. More than 50 people have contributed to background research to ensure the event programme meets the needs of both the pharma and med-tech sectors, as well as the NHS.
   

Key speakers
 

Speakers will include the ministerial lead for life sciences policy and NHS innovation, Lord O’Shaughnessy, who will lead the first keynote session on the theme of ‘Implementing the Life Sciences Industrial Strategy’.
 

The second keynote session of the day on the theme of
Strengthening collaboration with NHS and industry’, will be led by Ian Dodge, National Director, Strategy and Innovation, NHS England.
 

Another key speaker will be Steve Oldfield, the Department of Health and Social Care’s chief commercial officer and the person charged with renegotiating the £8bn pharmaceutical pricing regulation scheme, who will be a panellist on a session about ‘Negotiating the PPRS – Assessing what comes next’.
 

Representatives from NICE, MHRA and ABPI will also be among those involved in the wide-ranging debates which will help guests to understand how to develop relationships with and deliver innovation to the NHS.
   

An overview of the agenda
  ·        

Candid and open discussion about access and pricing as the deadline for completing PPRS negotiations rapidly approaches
  ·        

Keynote sessions in which NHS England and STP leaders outline their strategic vision and what role the life sciences sector can play in supporting it
  ·        

Lively debate about the Life Sciences Industrial Strategy and how barriers between industry and NHS can be broken down to realise its goals
  ·        

Opportunity for industry and the newly established RMOCs to engage in a dialogue about medicines optimisation and what specific challenges the NHS faces in terms of eliminating waste and variation to meet the efficiency agenda
  ·        
Breakout sessions in which AHSNs, industry and the NHS can discuss service redesign, patient pathways and the innovation from industry that’s required to deliver an ambitious programme of transformation
  ·        

Clarity on the role of NICE and the chance to feedback on the
Health Technology Assessment (HTA) process
  ·  

Increased knowledge of the challenges and changes in the NHS at a national level in terms of specialised commissioning and at a local level  

Conclusion
 

There is a pressing need for the pharma and med tech sectors to work more closely with the NHS, to maximise value for money while also ensuring access to innovative medicines and devices. The HSJ Life Sciences Forum is a unique opportunity for industry and the NHS to come together to discuss their challenges and identify solutions.
 

For more information about the event and details on how to sign up for it, please visit https://lifesciences.hsj.co.uk/                                                                               
                                                                              Ends  

Sarah Eglington is Client Services Director at Wilmington Healthcare. For information on Wilmington Healthcare, log on to
www.wilmingtonhealthcare.com

18th April 2018

Share

Company Details

Wilmington Healthcare

01268 495600

Contact Website

Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom

Latest content on this profile

Covid-19: how is it impacting on the NHS Long-term Plan?
Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in jeopardy
Wilmington Healthcare
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it
Wilmington Healthcare
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve
Wilmington Healthcare
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond
Wilmington Healthcare
2019: A pivotal year for the NHS
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the key changes in the NHS in 2019
Wilmington Healthcare
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan
Wilmington Healthcare